Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsPaul Wang, MD
Associate Clinical ProfessorAbout
Research
Publications
2025
5.4 Clinical Trial and Biomarker Signals for a GABA-B Agonist in Autism
Wang P. 5.4 Clinical Trial and Biomarker Signals for a GABA-B Agonist in Autism. Journal Of The American Academy Of Child And Adolescent Psychiatry 2025, 64: s157-s158. DOI: 10.1016/j.jaac.2025.07.700.Peer-Reviewed Original ResearchA Blueprint for Translational Precision Medicine in Autism Spectrum Disorder and Related Neurogenetic Syndromes
Thom R, Warren T, Khan S, Muhle R, Wang P, Brennand K, Zürcher N, Veenstra-VanderWeele J, Hoffman E. A Blueprint for Translational Precision Medicine in Autism Spectrum Disorder and Related Neurogenetic Syndromes. Journal Of Child And Adolescent Psychopharmacology 2025, 35: 178-193. PMID: 40138183, PMCID: PMC12344128, DOI: 10.1089/cap.2025.0023.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderNeurogenetic syndromesSpectrum disorderNeurobiology of autism spectrum disordersRett syndromeTarget engagementEvaluation of target engagementPlacebo responseEvaluate target engagementClinical trialsClinical trial design strategiesIntermediate phenotypesPreclinical model systemsTreatment discoveryObjectives:Trial design strategiesTrofinetideMolecular targetsNeurobiologyFace validityHuman clinical trialsPrecision medicineStem cell model systemsPrecision medicine approachIdentification of molecular targets
2024
Parent-Reported Outcome Measures for Individuals with Fragile X Syndrome: Clinically Meaningful Change Thresholds
Nelson M, Schmitt L, Horn P, Berry-Kravis E, Hessl D, Shaffer R, Carpenter R, Budimirovic D, Wang P, Reisinger D, Walton-Bowen K, Erickson C. Parent-Reported Outcome Measures for Individuals with Fragile X Syndrome: Clinically Meaningful Change Thresholds. Journal Of Autism And Developmental Disorders 2024, 56: 1658-1670. PMID: 39579284, DOI: 10.1007/s10803-024-06634-6.Peer-Reviewed Original ResearchConceptsFragile X syndromeABC-CFXVineland-IIPlacebo-controlled studyDisruptive behaviorX syndromeVisual analog scalePhase 3 clinical trialsParent-reported outcome measuresCGI-IPSI subscaleRelevant subscalesParent reportMeaningful change thresholdsOutcome measuresTreatment outcome resultsSubscalesTreatment week 8Double-blindArbaclofenVisual analog scale subscaleClinical outcome assessmentsWeek 8AnxietyAnchor-based analyses5.65 Arbaclofen Trial for Youth With ASD: European and Canadian Trials
Parellada M, Wang P, San Jose A, Calvo R, Nicolson R, Moscoso A, Frei J, Kushki A, Walton-Bowen K, Gonzalez-Navarro P, Anagnostou E. 5.65 Arbaclofen Trial for Youth With ASD: European and Canadian Trials. Journal Of The American Academy Of Child And Adolescent Psychiatry 2024, 63: s276-s277. DOI: 10.1016/j.jaac.2024.08.386.Peer-Reviewed Original ResearchPoints to consider when initiating clinical investigations in autistic paediatric populations–A White Paper
Ham L, Staunton H, Schulz J, Tillmann J, Volz D, Murtagh L, Chatham C, O'Connor E, Chamberlain S, Schoenenberger P, Pandina G, Wang P, Kas M, Arango C, Murphy D. Points to consider when initiating clinical investigations in autistic paediatric populations–A White Paper. European Neuropsychopharmacology 2024, 86: 35-42. PMID: 38917772, DOI: 10.1016/j.euroneuro.2024.05.011.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderSymptoms of autism spectrum disorderCore symptomsPaediatric clinical trialsClinical development programmeClinical trialsCore symptoms of autism spectrum disorderEveryday adaptive functioningEffectiveness of treatment approachesDegree of impairmentEarly developmental periodLong-term outcomesRepetitive behaviorsFood and Drug AdministrationSpectrum disorderAdaptive functioningEvidence of efficacyNeurodevelopment disordersDevelopmental periodPaediatric populationPharmacological therapySocial interactionClinical investigationPharmacological interventionsDrug Administration
2023
EDITS: An Easy-to-difficult Training Strategy for Cloud Failure Prediction
Lin Q, Li T, Zhao P, Liu Y, Ma M, Zheng L, Chintalapati M, Liu B, Wang P, Zhang H, Dang Y, Rajmohan S, Zhang D. EDITS: An Easy-to-difficult Training Strategy for Cloud Failure Prediction. 2023, 371-375. DOI: 10.1145/3543873.3584630.Peer-Reviewed Original ResearchCloud failuresFailure prediction approachTraining strategyReliability of cloud servicesState-of-the-artCurriculum learning methodState-of-the-art time series modelsOnline service systemsFailure predictionPrediction approachFailure prediction modelsCloud servicesCurriculum learningPublic datasetsLearning methodsCloudPrediction modelExperimental resultsService reliabilityService systemProactive actionsPerformanceFinancial lossesServicesTrainingEditorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m)
Beversdorf D, Anagnostou E, Hardan A, Wang P, Erickson C, Frazier T, Veenstra-VanderWeele J. Editorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m). Frontiers In Psychiatry 2023, 13: 1079006. PMID: 36741580, PMCID: PMC9893852, DOI: 10.3389/fpsyt.2022.1079006.Peer-Reviewed Original Research
2022
Multi-task Hierarchical Classification for Disk Failure Prediction in Online Service Systems
Liu Y, Yang H, Zhao P, Ma M, Wen C, Zhang H, Luo C, Lin Q, Yi C, Wang J, Zhang C, Wang P, Dang Y, Rajmohan S, Zhang D. Multi-task Hierarchical Classification for Disk Failure Prediction in Online Service Systems. 2022, 3438-3446. DOI: 10.1145/3534678.3539176.Peer-Reviewed Original ResearchDisk failure prediction modelDisk failure predictionOnline service systemsData imbalance problemDisk failuresImbalance problemMulti-task learningState-of-the-artFailure prediction modelsFailure predictionFailure prediction techniquesService systemDisk errorsPublic datasetsPrediction taskPrediction modelService disruptionPrediction techniquesPractical performanceService reliabilityHierarchical classificationI/O delaysMicrosoftProduction teamSystem reliability
2021
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1
Parellada M, San José Cáceres A, Palmer M, Delorme R, Jones E, Parr J, Anagnostou E, Murphy D, Loth E, Wang P, Charman T, Strydom A, Arango C. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1. Frontiers In Psychiatry 2021, 12: 701729. PMID: 34504446, PMCID: PMC8421761, DOI: 10.3389/fpsyt.2021.701729.Peer-Reviewed Original ResearchAutism spectrum disorderSocial functioningSocial communicationFluent speechSpectrum disorderVineland Adaptive Behavior ScalesAdaptive Behavior ScalesFamily qualityYoung autistic individualsDouble-blindDiagnosis of ASDCGI-IAutism symptomsPlacebo-controlled studyElectrophysiological markersBehavior problemsAutistic individualsBehavior ScaleSocial difficultiesAdaptive functioningAutistic childrenHealth-related qualityArbaclofenAutismPlacebo-ControlledClinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities
Krishnan M, Berry-Kravis E, Capal J, Carpenter R, Gringras P, Hipp J, Miller M, Mingorance A, Philpot B, Pletcher M, Rotenberg A, Tjeertes J, Wang P, Willgoss T, de Wit M, Jeste S. Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities. Nature Reviews Drug Discovery 2021, 20: 653-654. PMID: 34002058, DOI: 10.1038/d41573-021-00085-9.Peer-Reviewed Original Research